Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Oncology Panel 150

AltheaDx has received CLIA validation for a next-generation sequencing panel for its pharma services program. The AltheaDx Oncology Panel 150 (AOP 150) is a targeted, NGS assay for drug and companion diagnostic development programs, and simultaneously tests 143 solid tumor genes. The panel is based on Thermo Fisher Scientific's Oncomine Comprehensive Assay and runs on the Ion Torrent NGS platform. It s designed to work with minimal sample input per run and is well-suited for analysis of tumor samples extracted from formalin-fixed paraffin-embedded tissue, including small biopsies and fine needle aspirates, AltheaDx said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.